Quintiles expanded its London-based phase I facility by 35 beds, bringing the total number of phase I beds in London to 105 and globally to 385. The CRO said this number will increase even further later this year as a result of the planned opening of a phase I unit in Hyderabad, India. That facility will initially have 50 beds with capacity for 100.
The larger London facility is adjacent to one of only five Biomedical Research Centres (BRCs) in the UK. BRC designation and associated funding is awarded by the government to encourage innovation and translational research in biomedicine. Quintiles said it will work closely with the BRC as appropriate.